W. L. Burland

859 total citations
31 papers, 633 citations indexed

About

W. L. Burland is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, W. L. Burland has authored 31 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 7 papers in Pediatrics, Perinatology and Child Health and 6 papers in Epidemiology. Recurrent topics in W. L. Burland's work include Immunodeficiency and Autoimmune Disorders (4 papers), Helicobacter pylori-related gastroenterology studies (4 papers) and Gastrointestinal motility and disorders (3 papers). W. L. Burland is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (4 papers), Helicobacter pylori-related gastroenterology studies (4 papers) and Gastrointestinal motility and disorders (3 papers). W. L. Burland collaborates with scholars based in United Kingdom and India. W. L. Burland's co-authors include J. Beresford, P C Sharpe, T. Hesselbo, Kate Simpson, N. R. Butler, G J Milton-Thompson, R M Lee, B. Brozović, R. I. Gleadle and G. V. Groom and has published in prestigious journals such as The Lancet, Gastroenterology and Gut.

In The Last Decade

W. L. Burland

27 papers receiving 528 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W. L. Burland United Kingdom	13	180	166	95	89	86	31	633
R I Russell United Kingdom	14	151 0.8×	66 0.4×	35 0.4×	74 0.8×	95 1.1×	28	416
W. A. Stack United Kingdom	14	367 2.0×	302 1.8×	61 0.6×	119 1.3×	96 1.1×	25	809
S. G. Flavell Matts United Kingdom	11	177 1.0×	70 0.4×	49 0.5×	53 0.6×	33 0.4×	47	600
F Ciccimarra Italy	14	121 0.7×	68 0.4×	90 0.9×	134 1.5×	10 0.1×	35	559
Patricia Forget Belgium	18	217 1.2×	114 0.7×	57 0.6×	411 4.6×	86 1.0×	61	1.0k
Nabila Turjman United States	14	143 0.8×	63 0.4×	16 0.2×	133 1.5×	41 0.5×	20	590
Elisabetta Surrenti Italy	11	233 1.3×	200 1.2×	57 0.6×	54 0.6×	38 0.4×	22	457
M Perrin‐Fayolle France	15	121 0.7×	109 0.7×	86 0.9×	82 0.9×	54 0.6×	81	983
O. Dhodanand Kowlessar United States	18	271 1.5×	229 1.4×	22 0.2×	180 2.0×	12 0.1×	35	909
Guido Hanauer Germany	9	310 1.7×	84 0.5×	148 1.6×	222 2.5×	36 0.4×	22	602

Countries citing papers authored by W. L. Burland

Since Specialization

Citations

This map shows the geographic impact of W. L. Burland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. L. Burland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. L. Burland more than expected).

Fields of papers citing papers by W. L. Burland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. L. Burland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. L. Burland. The network helps show where W. L. Burland may publish in the future.

Co-authorship network of co-authors of W. L. Burland

This figure shows the co-authorship network connecting the top 25 collaborators of W. L. Burland. A scholar is included among the top collaborators of W. L. Burland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. L. Burland. W. L. Burland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Deakin, Mark, et al.. (1987). Large single daily dose of histamine H2 receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacological study.. Gut. 28(5). 566–572. 20 indexed citations

Gledhill, T, et al.. (1984). Studies on the cimetidine resistant duodenal ulcer: A summary of work performed at the Royal Naval Hospital, Haslar. Journal of The Royal Naval Medical Service. 70(2). 70–81. 1 indexed citations

Griffiths, R R, et al.. (1982). Oxmetidine: clinical pharmacological studies with a new H2-receptor antagonist.. Gut. 23(2). 157–163. 19 indexed citations

McLeod, M. E., et al.. (1981). Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK&F 92657); a new antihypertensive agent.. British Journal of Clinical Pharmacology. 12(4). 567–572. 4 indexed citations

Burland, W. L., et al.. (1980). Cimetidine treatment fortheprevention ofrecurrence ofduodenal ulcer: aninternational collaborative study.

Boyce, Malcolm, et al.. (1980). Assessment in man of SK & F 92657, a novel compound with vasodilator and beta‐adrenoceptor blocking activity [proceedings]. British Journal of Clinical Pharmacology. 9(3). 299P–299P. 12 indexed citations

Burland, W. L., et al.. (1980). Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study. Postgraduate Medical Journal. 56(653). 173–176. 76 indexed citations

Burland, W. L., et al.. (1975). Pharmacological evaluation of cimetidine, a new histamine H2‐receptor antagonist, in healthy man.. British Journal of Clinical Pharmacology. 2(6). 481–486. 173 indexed citations

Burland, W. L.. (1975). Treatment of duodenal ulcer by metiamide. The Lancet. 306(7939). 779–781. 30 indexed citations

10.

Burland, W. L.. (1973). Fenfluramine and haemolytic anaemia.. BMJ. 1(5850). 419.5–419. 1 indexed citations

11.

Kerr, M. M., et al.. (1973). Absorption and excretion of cephalexin by the newborn infant.. Archives of Disease in Childhood. 48(2). 147–150. 6 indexed citations

12.

Holme, Tord, et al.. (1972). A trial to compare reactions and responses to BCG vaccine prepared from Copenhagen 1331 and glaxo 1077 strains. Tubercle. 53(2). 100–105. 5 indexed citations

13.

Holme, Tord, et al.. (1972). A trial to compare United Kingdom strength BCG vaccine with vaccine of double the moist weight content. Tubercle. 53(2). 106–110. 6 indexed citations

14.

Burland, W. L., et al.. (1970). BCG vaccination of new-born infants: a comparison between jet and syringe injection.. Medical officer. 124(20).

15.

Burland, W. L., et al.. (1969). Intradermal measles vaccination.. Medical officer. 121(8). 99–100. 1 indexed citations

16.

Butler, N. R., et al.. (1969). Advantages of Aluminium Hydroxide Adsorbed Combined Diphtheria, Tetanus, and Pertussis Vaccines for the Immunization of Infants. BMJ. 1(5645). 663–666. 76 indexed citations

17.

Burland, W. L.. (1969). Measles vaccination by the intradermal route. Postgraduate Medical Journal. 45(523). 323–326. 6 indexed citations

18.

Burland, W. L., et al.. (1968). Reactions to combined diphtheria, tetanus and pertussis vaccine: a comparison between plain vaccine and vaccine adsorbed on aluminium hydroxide.. Medical officer. 119(2). 17–19. 5 indexed citations

19.

Burland, W. L., et al.. (1967). Effect of different doses of attenuated measles virus by the intradermal route.. Medical officer. 117(17). 1 indexed citations

20.

Burland, W. L.. (1964). Diabetes mellitus syndrome in the newborn infant. The Journal of Pediatrics. 65(1). 122–123. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact